Four more drugs in keenly watched ALS trial miss the mark

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 HEALEY ALS basket trial, which is trying to accelerate the search for new therapies for the devastating neurodegenerative disease.